secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001493152-22-012893
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months
--------------------------------------------------------------------------------

- 24 patients treated; no cases of rejection or intraocular inflammation reported.
- Cohort 4 (impaired vision) averaged 7.6-letter gain in study eye at Month 12; 25% gained ≥15 letters.
- Five Cohort 4 subjects with OpRegen delivered to most/all GA area had average 12.8-letter gain and outer retinal structure improvement.
- Majority of AEs were mild (Cohort 4: 93%); most common ocular AEs related to surgical procedure (conjunctival hemorrhage, epiretinal membrane).
- OpRegen developed under worldwide collaboration with Roche and Genentech; larger controlled study needed to confirm findings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/0001493152-22-012893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222012893/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer